MX9707191A - Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases. - Google Patents
Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases.Info
- Publication number
- MX9707191A MX9707191A MX9707191A MX9707191A MX9707191A MX 9707191 A MX9707191 A MX 9707191A MX 9707191 A MX9707191 A MX 9707191A MX 9707191 A MX9707191 A MX 9707191A MX 9707191 A MX9707191 A MX 9707191A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibition
- treatment
- alkyl
- compounds useful
- proliferative diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
A method of inhibiting Ras function and therefore inhibiting cellular growth is disclosed. The method comprises the administration of a novel compound of formula (Ia), (Ib) or (Ic) wherein: R and R1 are H, alkyl, halogeno, OH, alkoxy, NH2, alkylamino, dialkylamino, CF3, SO3H, CO2R3, NO2, SO2NH2, or CONHR4; n is 0 or 1; R2 is a group of the formula R5C(O)-, R5CH2C(O)-, R5C(R6)2C(O)-, R5SO2-, R5CH2SO2-, R5SCH2C(O)-, R5OC(O)-, R5NHC(O)-, R5C(O)C(O)- or R5SC(O)-; R5 is alkyl, aryl, arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl or heterocycloalkyl; and R6 is alkyl or C(R6)2 is a carboxyclic ring; or pharmaceutically acceptable salts thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08410442 | 1995-03-24 | ||
US08/410,442 US5684013A (en) | 1995-03-24 | 1995-03-24 | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
PCT/US1996/003306 WO1996030017A1 (en) | 1995-03-24 | 1996-03-20 | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
MX9707191A true MX9707191A (en) | 1997-11-29 |
MXPA97007191A MXPA97007191A (en) | 1998-07-03 |
Family
ID=
Also Published As
Publication number | Publication date |
---|---|
JP3001982B2 (en) | 2000-01-24 |
EP0814807A1 (en) | 1998-01-07 |
AU708244B2 (en) | 1999-07-29 |
HUP9801396A3 (en) | 2000-03-28 |
US5703090A (en) | 1997-12-30 |
US5958939A (en) | 1999-09-28 |
DE69627993T2 (en) | 2004-02-26 |
IL117603A (en) | 2001-01-28 |
TW473477B (en) | 2002-01-21 |
HUP9801396A2 (en) | 1999-05-28 |
ATE239472T1 (en) | 2003-05-15 |
KR19980703257A (en) | 1998-10-15 |
CA2216291C (en) | 2001-06-05 |
ES2198481T3 (en) | 2004-02-01 |
NZ305133A (en) | 1999-11-29 |
AR003936A1 (en) | 1998-09-30 |
DE69627993D1 (en) | 2003-06-12 |
US5684013A (en) | 1997-11-04 |
AU5307296A (en) | 1996-10-16 |
CA2216291A1 (en) | 1996-10-03 |
EP0814807B1 (en) | 2003-05-07 |
IL117603A0 (en) | 1996-07-23 |
WO1996030017A1 (en) | 1996-10-03 |
JPH10505102A (en) | 1998-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2216291A1 (en) | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases | |
CA2174105A1 (en) | Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases | |
IE900394L (en) | Thiazole derivatives | |
CA2173963A1 (en) | Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases | |
WO1991013055A3 (en) | New aryl- and heteroarylethenylene derivatives and process for their preparation | |
CA2269994A1 (en) | 7-hetero-bicyclo¬2.2.1|-heptanes | |
TW359670B (en) | Process for producing quinazolin-4-one derivatives | |
CA2160444A1 (en) | Aroyl-piperdine derivatives | |
EP0322738A3 (en) | Benzylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells | |
HU9202105D0 (en) | Tetrahydro-pyrrholo(1,2-a)pyrazine-4-spiro-3'-pyrrholidine derivatives method for producing them and pharmaceutical preparatives containing them | |
MXPA02006329A (en) | Substituted 8arylquinoline phosphodiesterase4 inhibitors. | |
EP0825189A4 (en) | 1,4-benzodioxin derivatives | |
EP0335979A4 (en) | Thienopyrimidine derivatives | |
IE64851B1 (en) | New bronchospasmolytic compounds and process for their preparation | |
EP1048655A4 (en) | 1,2-dihydro-2-oxoquinoline derivatives | |
ES2128960A1 (en) | Fluorophenyl-triazine and pyrimidine derivatives as compounds acting on the central nervous system | |
IE45096L (en) | Thiadiazole derivatives | |
CA2293368A1 (en) | Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives useful for inhibition of farnesyl protein transferase | |
ES8705363A1 (en) | Tetrahydronaphthalenols for the treatment of hypertension. | |
GB1505859A (en) | Azetidinone derivatives | |
GR3002688T3 (en) | Thiadiazolylacetamide derivatives, process for the preparation thereof and their use | |
HU9202849D0 (en) | Method for producing n,n',n-trisubstituted- 5-bis-amino-methylene-1,3-dioxane-4,6-dione derivatives and pharmaceutical preparatives containing them | |
ATE260905T1 (en) | (PHENYLALKYLAMINOALKYLOXY)-HETERO-ARYL COMPOUNDS AND PROCESSES AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS | |
CA2293373A1 (en) | Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase | |
NO912341L (en) | PROCEDURE FOR THE PREPARATION OF HIV REVERS TRANSCIPTASE INHIBITORS. |